Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients

Br J Clin Pharmacol. 1998 Apr;45(4):412-5. doi: 10.1046/j.1365-2125.1998.t01-1-00704.x.


Aims: Ropinirole is a specific non-ergoline dopamine D2-receptor agonist with antiparkinsonian properties. The pharmacokinetic parameters of ropinirole taken in the fasted condition were compared with those when it was co-administered with food.

Methods: This was an open, randomized, two sessions cross over study in 12 patients with Parkinson's disease, comparing the steady-state pharmacokinetic profiles of ropinirole on two different study days: 'fasted' and 'fed'.

Results: The mean Cmax was lower in the 'fed' regimen than in the 'fasted' one (-25%, P=0.002). The median tmax was observed 2.6 h later in the 'fed' regimen than in the 'fasted' regimen (P<0.05). There was a slight but significant decrease in AUC(0,8 h) in the 'fed' regimen (P=0.03).

Conclusions: Food decreases the rate of absorption of ropinirole, but has little effect on the extent of absorption.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / pharmacokinetics*
  • Antiparkinson Agents / therapeutic use
  • Area Under Curve
  • Female
  • Food-Drug Interactions*
  • Half-Life
  • Humans
  • Indoles / adverse effects
  • Indoles / pharmacokinetics*
  • Indoles / therapeutic use
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism*


  • Antiparkinson Agents
  • Indoles
  • ropinirole